
Claims:

1. ~~A method of treating a hematological malignancy comprising administering to a subject in need thereof an effective amount~~ Use of (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one, having the structure




, or a pharmaceutically acceptable salt thereof and ~~an effective amount of~~ venetoclax or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a hematological malignancy in a subject in need thereof, wherein an effective amount of the (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one, or a pharmaceutically acceptable salt thereof and an effective amount of the venetoclax, or a pharmaceutically acceptable salt thereof is to be administered to the subject.

2. The ~~method~~ use of claim 1, wherein the ~~method comprises administering~~ (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or a pharmaceutically acceptable salt thereof is to be administered sequentially, separately or simultaneously with venetoclax or a pharmaceutically acceptable salt thereof.


3. The ~~method~~ use of claim 1 or 2, wherein the hematological malignancy is selected from acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML), chronic lymphocytic leukaemia (CLL), and chronic myelomonocytic leukemia (CMML).

4. A compound (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one, having the structure



, or a pharmaceutically acceptable salt thereof for use in the treatment of a hematological malignancy, wherein the treatment comprises separate, sequential or simultaneous administration of venetoclax or a pharmaceutically acceptable salt thereof.

5. A compound Venetoclax or a pharmaceutically acceptable salt thereof for use in the treatment of a hematological malignancy, wherein the treatment comprises separate, sequential or simultaneous administration of (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one, having the structure



, or a pharmaceutically acceptable salt thereof.

6. The compound or the pharmaceutically acceptable salt thereof for use of claim 4 or 5, wherein the hematological malignancy is selected from acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML), chronic lymphocytic leukaemia (CLL), and chronic myelomonocytic leukemia (CMML).

7. The ~~method or~~ use of any one of claims 1 to ~~6~~3, ~~which further comprises administering~~ wherein an effective amount of 5-azacitidine is to be further administered.

8. The compound or the pharmaceutically acceptable salt thereof for use of any one of claims 4 to 6, wherein an effective amount of 5-azacitidine is to be further administered.


~~8~~9. The ~~method or~~ use of claim 3 ~~or 6~~, wherein the hematological malignancy is a relapsed or refractory hematological malignancy.

10. The compound or the pharmaceutically acceptable salt thereof for use of claim 6, wherein the hematological malignancy is a relapsed or refractory hematological malignancy.

~~9~~11. The ~~method or~~ use of claim 3 ~~or 6~~, wherein the hematological malignancy is resistant to a monotherapy of a BCL-2 inhibitor.

12. The compound or the pharmaceutically acceptable salt thereof for use of claim 6, wherein the hematological malignancy is resistant to a monotherapy of a BCL-2 inhibitor.


~~10~~13. A kit comprising:

a first pharmaceutical composition comprising (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one, having the structure , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier; and

a second pharmaceutical composition comprising venetoclax or a pharmaceutically acceptable salt thereof and instructions for use.

~~11~~14. The kit of claim ~~10~~13, which further comprises a third pharmaceutical composition comprising 5-azacitidine.

~~12~~15. A pharmaceutical product comprising i) (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one,

having the structure , or a pharmaceutically acceptable salt thereof, and ii) venetoclax or a pharmaceutically acceptable salt thereof.

~~13~~16. The pharmaceutical product of claim 15, wherein (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or a pharmaceutically acceptable salt thereof and venetoclax or a pharmaceutically acceptable salt thereof are present in a single dosage form.

~~14~~17. The pharmaceutical product of claim 15, wherein (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or a pharmaceutically acceptable salt thereof and venetoclax or a pharmaceutically acceptable salt thereof are present in separate dosage forms.